Summary
This 8-K filing from BeOne Medicines Ltd. (ONC) reports two significant developments for the company in early September 2020. Firstly, its ordinary shares were admitted to the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2020. This inclusion is expected to enhance liquidity and potentially broaden the investor base by allowing mainland Chinese investors access to its Hong Kong-listed shares. Additionally, the company's shares were added to the Hang Seng Composite Index (HSCI), a widely followed benchmark in Hong Kong, which may lead to increased institutional interest and investment flows into the stock.
Key Highlights
- 1BeiGene's ordinary shares included in Shanghai-Hong Kong Stock Connect effective September 7, 2020.
- 2BeiGene's ordinary shares included in Shenzhen-Hong Kong Stock Connect effective September 7, 2020.
- 3BeiGene's ordinary shares added to the Hang Seng Composite Index (HSCI).
- 4Health Canada accepted New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for Waldenström’s macroglobulinemia (WM).
- 5BRUKINSA® (zanubrutinib) NDS granted priority review status by Health Canada.
Frequently Asked Questions
Inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs allows mainland Chinese investors to trade BeiGene's Hong Kong-listed shares, potentially increasing trading volume, liquidity, and broadening the company's investor base.
Inclusion in the HSCI, a major Hong Kong stock market index, often leads to increased visibility and potential investment from index-tracking funds and institutional investors, which can positively impact stock performance.
Health Canada has accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) for the treatment of Waldenström’s macroglobulinemia (WM) and has granted it priority review status, indicating a potentially expedited review process.
Priority review status typically means that a regulatory agency, in this case, Health Canada, will expedite the review process for the drug submission, potentially leading to a faster marketing approval decision.